Cargando…
P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430939/ http://dx.doi.org/10.1097/01.HS9.0000847492.88194.df |
| _version_ | 1784779915495735296 |
|---|---|
| author | Lansigan, F. Andorsky, D. J. Coleman, M. Yacoub, A. Melear, J. M. Fanning, S. R. Kolibaba, K. S. Reynolds, C. Nowakowski, G. S. Gharibo, M. Ahn, J. R. Li, J. Rummel, M. J. Sharman, J. P. |
| author_facet | Lansigan, F. Andorsky, D. J. Coleman, M. Yacoub, A. Melear, J. M. Fanning, S. R. Kolibaba, K. S. Reynolds, C. Nowakowski, G. S. Gharibo, M. Ahn, J. R. Li, J. Rummel, M. J. Sharman, J. P. |
| author_sort | Lansigan, F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430939 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94309392022-08-31 P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS Lansigan, F. Andorsky, D. J. Coleman, M. Yacoub, A. Melear, J. M. Fanning, S. R. Kolibaba, K. S. Reynolds, C. Nowakowski, G. S. Gharibo, M. Ahn, J. R. Li, J. Rummel, M. J. Sharman, J. P. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430939/ http://dx.doi.org/10.1097/01.HS9.0000847492.88194.df Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Lansigan, F. Andorsky, D. J. Coleman, M. Yacoub, A. Melear, J. M. Fanning, S. R. Kolibaba, K. S. Reynolds, C. Nowakowski, G. S. Gharibo, M. Ahn, J. R. Li, J. Rummel, M. J. Sharman, J. P. P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_full | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_fullStr | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_full_unstemmed | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_short | P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS |
| title_sort | p1156: magnify phase 3b study of lenalidomide + rituximab (r2) followed by maintenance in relapsed/refractory indolent non-hodgkin lymphoma: complete induction phase analysis |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430939/ http://dx.doi.org/10.1097/01.HS9.0000847492.88194.df |
| work_keys_str_mv | AT lansiganf p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT andorskydj p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT colemanm p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT yacouba p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT melearjm p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT fanningsr p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT kolibabaks p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT reynoldsc p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT nowakowskigs p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT gharibom p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT ahnjr p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT lij p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT rummelmj p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis AT sharmanjp p1156magnifyphase3bstudyoflenalidomiderituximabr2followedbymaintenanceinrelapsedrefractoryindolentnonhodgkinlymphomacompleteinductionphaseanalysis |